Authors
Latest:
Timothy McClure, MD, on patient selection for focal therapyTimothy D. McClure outlines his approach to patient selection with focal therapy as well as how NanoKnife fits into that landscape.
Latest:
Expert discusses the NMIBC trials landscape"It’s a very good time to be taking care of patients with bladder cancer," says Joshua J. Meeks, MD, PhD.
Latest:
Study results affirm effectiveness of evolving prostate cancer therapies“I think it does give us confidence that clinical trials can predict how these drugs will work in the real world," says Stephen J. Freedland, MD.
Latest:
Insights on Perirectal Spacing in Prostate CancerIn the first article of this series, Juan Montoya, MD, discusses advances in perirectal spacing in the treatment of prostate cancer.
Latest:
Integrating video visits into urologic training"Now is the time for programs to leverage their existing telehealth platforms and practices for trainee education while continuing to serve patients," the authors write.
Latest:
David Stanley, MD, on current trends in the management of kidney stonesDavid Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.
Latest:
Taylor Goodstein, MD, highlights project on staging in larger kidney tumors“What we've been working on is a giant 30,000 patient database study using the National Cancer Database to see exactly what the rates are of upstaging and downstaging for these larger kidney tumors,” says Taylor Goodstein, MD.
Latest:
Clinical Pearls for Community Urologists Treating Patients with MIBCDr Chamie shares advice for community urologists treating patients with MIBC.
Latest:
PSMA PET-CT Imaging: Impact on Real-World Diagnosis and Management of Prostate CancerIn this companion article, Jaideep S. Sohi, MD, shares insights on PSMA-PET imaging’s impact on real-world diagnosis and management of prostate cancer.
Latest:
US Urology Partners Names Healthcare Visionary Raoul S. Concepcion, MD, as Chief Science OfficerConcepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.
Latest:
Letter: Declassifying Gleason 6 as a cancer would do more harm than good"We feel a more appropriate approach would be to retain true Gleason 6 as a cancer of extremely low metastatic potential requiring close follow-up," write Harris et al.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Study: CVAC System doesn't raise intrarenal pressure in treating kidney stones"What we showed was that there's no difference in the pressures whether you use CVAC or standard ureteroscopy," says Roger Sur, MD.
Latest:
Does varicocele affect prostate cancer outcomes?"We found that with a 5-year Kaplan-Meier survival analysis that patients with varicocele had worse outcomes than patients without varicocele," says Muhammed A. Moukhtar Hammad, MBBCh.
Latest:
Tips for Improving the Interpretation and Reporting of PSMA-PET Imaging ResultsTony Abraham, DO, MPA, outlines the limitations of PSMA-PET imaging and discusses the importance of multidisciplinary care in overcoming challenges surrounding the interpretation and reporting of imaging results.
Latest:
Arvin K. George, MD, provides update on the PRESERVE trialThe PRESERVE trial is evaluating the safety and effectiveness of Irreversible electroporation for prostate tissue ablation.
Latest:
PINNACLE trial aims to confirm pilot success with BPH drug-coated balloon catheterThe drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.
Latest:
Sandip Prasad, MD, on the approval of mitomycin intravesical solution for LG-IR-NMIBCSandip M. Prasad, MD, MPhil, shares his thoughts on the impact of the FDA approval of mitomycin for intravesical solution for patients with LG-IR-NMIBC.
Latest:
Kate Gessner, MD, on systemic agents vs MDT after kidney cancer progression“In the setting of widespread metastatic progression or failure, we typically prefer more systemic therapy with metastasis-directed therapy for symptomatic sites,” says Kate H. Gessner, MD, PhD.
Latest:
Real-world studies compare overall survival between ARPIs in mCSPC"Overall, these findings add to the growing body of evidence that [shows that] apalutamide may offer a survival advantage in real-world setting in patients with metastatic castration-sensitive prostate cancer," says Mehmet A. Bilen, MD.
Latest:
Closing Thoughts on the Impact of PSMA-PET Imaging in Prostate CancerExperts summarize how the use of PSMA-PET imaging has impacted the field to date and share their hopes for the future.
Latest:
A physician’s advice for defusing patient angerRebekah Bernard, MD, provides tips for improving interactions with patients who are angry.
Latest:
Urology Practice advice: prioritize billing and coding oversightWhen a miscoded procedure is the result of substantial negligence or fraud, it can be detrimental to a medical practice or physician.
Latest:
Challenges in plasmacytoid urothelial carcinoma underscore need for novel treatment options“If patients are not experiencing a clear clinical benefit for chemotherapy prior to surgery, we need to be really thoughtful about how we use it,” says Fed Ghali, MD.
Latest:
Tim Richardson, MD, on genetic testing in the era of targeted therapies“Before long, what we do, how we do it, and when we do it might solely be based off of those genetic testing results,” says Tim Richardson, MD.
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
Matthew Cooperberg, MD, on racial disparities in prostate, bladder cancer outcomes“Black patients have over 2-fold excess mortality compared to White men, and that has been fairly consistent; the actual rate ratio has hovered between 2 and 2.5 for many years,” says Matthew R. Cooperberg, MD, MPH.
Latest:
Perioperative outcomes support benefit of TAR-200 plus cetrelimab in MIBC"Provided that we will confirm the efficacy data long-term, there is an opportunity to spare, de-escalate a bit, the treatment in select patients, and to expose the patient with inferior risk of developing severe [adverse] effects," says Andrea Necchi, MD.
